Compare Ecopetrol SA (EC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Neurocrine Biosciences Inc — how do they compare? Ecopetrol SA trades at $15.99 (market cap $30.44B), while Neurocrine Biosciences Inc trades at $170.91 (market cap $17.30B). The key difference: Ecopetrol SA is the larger of the two by market cap, and Ecopetrol SA pays a 4.06% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| EC | NBIX | |
|---|---|---|
Market Cap | $30.44B | $17.30B |
Sector | Energy | Health |
52-Week High | $16.58 | $180.55 |
52-Week Low | $8.29 | $123.10 |
Enterprise Value | $58.23B | $16.39B |
Dividend Yield | 4.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.16, up 1.76% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company maintains solid profitability with an 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6T in 2022 to $119.7T in 2025. Recent developments include a finalized labor agreement with the USO union and S&P affirming its BB- credit rating with a stable outlook on June 17, 2026.
The stock presents a mixed outlook: valuation appears reasonable with a P/E of 11.39, but earnings misses and declining revenue pose risks. Analyst consensus is cautious with a $14.63 price target below current levels. Key opportunities include stable cash flow and dividend payments, while risks involve oil price volatility and execution challenges in a competitive energy sector.
Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.
Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
